Journal
NATURE BIOTECHNOLOGY
Volume 24, Issue 8, Pages 1005-1015Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt1223
Keywords
-
Categories
Funding
- NCI NIH HHS [5T32 CA 00911-28, 1U54 CA 119313] Funding Source: Medline
- NIGMS NIH HHS [2P01 GM 059299] Funding Source: Medline
Ask authors/readers for more resources
Technologies that mediate targeted delivery of small interfering RNAs (siRNAs) are needed to improve their therapeutic efficacy and safety. Therefore, we have developed aptamer-siRNA chimeric RNAs capable of cell type-specific binding and delivery of functional siRNAs into cells. The aptamer portion of the chimeras mediates binding to PSMA, a cell-surface receptor overexpressed in prostate cancer cells and tumor vascular endothelium, whereas the siRNA portion targets the expression of survival genes. When applied to cells expressing PSMA, these RNAs are internalized and processed by Dicer, resulting in depletion of the siRNA target proteins and cell death. In contrast, the chimeras do not bind to or function in cells that do not express PSMA. These reagents also specifically inhibit tumor growth and mediate tumor regression in a xenograft model of prostate cancer. These studies demonstrate an approach for targeted delivery of siRNAs with numerous potential applications, including cancer therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available